Description

Medtronic’s Hypertension Breakthrough: The Journey From 50,000 to 2.5 Million Patients—A Silent Market Awakening!

Medtronic plc reported its fiscal 2026 third quarter results highlighting the strongest revenue growth in nearly three years, with 6% organic growth and 8.7% reported revenue reaching $9 billion. Key growth drivers include the Cardiovascular portfolio, particularly the Cardiac Ablation Solutions (CAS) business, which grew 80% year-over-year, driven primarily by pulsed field ablation (PFA) technologies such as the Affera platform and Sphere-9 catheter. These catheters are noted for safety, durability, and versatility, now used in varied atrial fibrillation procedures globally. The company is optimistic about future indications and geographic expansions for PFA, including launches in Japan and development of the Sphere-360 catheter.